Treatment options for hepatic encephalopathy (Q37735854)

22 August 2017

1 reference

title

Treatment options for hepatic encephalopathy (English)

1 reference

22 August 2017

Thomas D Schiano

1

1 reference

PubMed ID

20412036

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

22 August 2017

1 reference

22 August 2017

30

1 reference

22 August 2017

5 Pt 2

1 reference

22 August 2017

16S-21S

1 reference

Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

22 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.PT2.16S

21 January 2018

Hepatic Encephalopathy.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.PT2.16S

Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.PT2.16S

Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.PT2.16S

An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.PT2.16S

Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.PT2.16S

Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.PT2.16S

Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.PT2.16S

Rifaximin for the treatment of hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.PT2.16S

Rifaximin for treatment of hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.PT2.16S

Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.PT2.16S

Alternative pathway therapy for urea cycle disorders: twenty years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.PT2.16S

Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.PT2.16S

Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.PT2.16S

Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.PT2.16S

Probiotic yogurt for the treatment of minimal hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.PT2.16S

21 January 2018

Identifiers

DOI

10.1592/PHCO.30.PT2.16S

1 reference

22 August 2017

1 reference

PubMed ID

20412036